Pharmaceuticals

Zhengye Biotechnology

Zhengye Biotechnology released FY2025 Q2 earnings on December 12 (EST), actual revenue USD 4.345 M, actual EPS USD -0.0319

Zhengye Biotechnology released FY2025 Semi-Annual Earnings on December 12, 2025 (EST), with actual revenue of USD 8.636 M and EPS of USD -0.0634

Zhengye Biotechnology released FY2025 Q1 earnings on December 12 (EST), actual revenue USD 4.29 M, actual EPS USD -0.0315

Zhengye Biotechnology released FY2024 earnings on July 3, 2025 (EST), with actual revenue of USD 25.88 M and EPS of USD 0.0344

Zhengye Biotechnology released FY2024 Q4 earnings on July 3 (EST), actual revenue USD 6.261 M, actual EPS USD 0.0034

Zhengye Biotechnology released FY2024 9 Months Earnings on July 3, 2025 (EST) with actual revenue of USD 19.63 M and EPS of USD 0.0308

Zhengye Biotechnology released FY2024 Q3 earnings on July 3, 2025 (EST), with actual revenue of USD 6.519 M and EPS of USD 0.0035

Zhenye Bio-Technology Holdings Co. Ltd. Net Income Down in FY2024

Chengye Bio-Technology Holdings Receives NASDAQ Delisting Notice for Late 20-F Filing

ZYBT.US released FY2024 Semi-Annual Earnings on November 15 (BJT), with actual revenue of 13.11 M USD and EPS of 0.0272 USD

ZYBT.US released FY2024 Q1 earnings on November 15 (BJT) with actual revenue of 6.575 M USD and EPS of 0.0136 USD

ZYBT.US released FY2024 Q2 earnings on November 15 (BJT), with actual revenue of 6.533 M USD and EPS of 0.0135 USD

ZYBT.US released FY2023 Semi-Annual Earnings on November 15 (BJT), with actual revenue of 16.53 M USD and EPS of 0.0625 USD

ZYBT.US released FY2023 Q2 earnings on November 15 (BJT) with actual revenue of 8.038 M USD and EPS of 0.0303 USD

ZYBT.US released FY2023 Q1 earnings on November 15 (BJT) with actual revenue of 8.499 M USD and EPS of 0.0321 USD

ZYBT.US released FY2023 Q3 earnings on May 15 (BJT) with actual revenue of 6.492 M USD and EPS of 0.0169 USD

ZYBT.US released FY2023 Q4 earnings on May 15 (BJT), with actual revenue of 6.678 M USD and EPS of 0.0173 USD

ZYBT.US released FY2022 Q3 earnings on May 15, 2024 (BJT) with actual revenue of 9.57 M USD and EPS of 0.0361 USD

ZYBT.US released FY2022 Annual Earnings on May 15 (BJT), with actual revenue of 38.45 M USD and EPS of 0.1511 USD

ZYBT.US released FY2023 Annual Earnings on May 15 (BJT), with actual revenue of 29.68 M USD and EPS of 0.0965 USD

Rich Sparkle

Novabay Pharmac

Valens Semiconductor

Greenpower Motor

Alpha Tech

Offerpad Solutions

VCI Global

Tryhard

Tradr 2X Long APLD Daily ETF

ZeZentalis Pharma

Eli Lilly

Roche

ROCHE HOLDINGS AG

Astrazeneca

NOVARTIS AG

Novo Nordisk AS

Chugai Pharmaceutical

UCB S.A.

Daiichi Sankyo

Otsuka Pharmaceutical

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

Zhengye Biotechnology(ZYBT.US)